Blockchain Registration Transaction Record

Helus Pharma Touts Phase 3 Progress for HLP003, Plans HLP004 Study

Helus Pharma updates on HLP003 and HLP004: Phase 3 topline data for MDD expected Q4 2026, and a Phase 2 study for GAD planned for Q1 2027.

The update from Helus Pharma signals meaningful progress in the clinical development of novel serotonergic agonists for major depressive disorder and generalized anxiety disorder—conditions that affect millions worldwide and often resist existing treatments. If HLP003 and HLP004 succeed in later-stage trials, they could offer new mechanisms of action and potentially durable relief for patients who have not responded to conventional therapies. The FDA’s Breakthrough Therapy Designation for HLP003 underscores the unmet need and regulatory recognition of its therapeutic potential. For investors, the advancement of both programs toward regulatory submission and commercialization represents a significant value catalyst, while for patients and clinicians, it offers hope for expanded treatment options in mental health care.